Attention-deficit/hyperactivity disorder (ADHD) is a condition that is characterized by developmentally high levels of inattention, overactivity, and impulsivity, although the extent and distribution of symptoms often varies across individuals. ADHD often begins very early in childhood. Children with this condition are often unable to focus their attention on tasks, are easily distracted, fail to complete assignments, and shift from one play activity to another. They may also be extremely overactive and aggressive. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, groups ADHD symptoms into two domains: inattention and hyperactivity/impulsivity. Some children only manifest symptoms in one of these domains, although the majority have impairments in both. ADHD co-occurs with other psychiatric and cognitive conditions in approximately two thirds of cases. 1 Most common among these are oppositional and conduct problems (up to 50% of some samples), anxiety disorders (often approxiamtely 25% of cases), mood disorders (5% to 15%), and learning disorders (at least 20%). Children with ADHD are at risk for development of conduct and antisocial disorders, substance use disorders, academic underachievement, poor educational and vocational attainment, and secondary mood and anxiety disorders. Moreover, ADHD symptoms frequently persist into adulthood, with the majority of individuals showing some evidence of residual symptomatology or impairment, and a somewhat lower percentage having the full disorder. 2 Although ADHD has long been well known to pediatricians and specialists in child mental health, it was often unfamiliar to other disciplines. However, as information about the range of impairments associated with ADHD and its persistence over the lifespan have become more available, ADHD has attracted considerable interest. Not all of this attention has been positive; there have been concerns regarding the possibility of over-diagnosis and over-treatment, with particular focus on the large increase in stimulant medication use over the past decade. 34 Some have alleged that ADHD is better conceptualized as a problem of temperament, rather than a psychiatric disorder, or a reflection of a mismatch between the developmental needs of children and those of an increasingly achievement oriented society. The public dialogue regarding these issues has led to several comprehensive reviews of ADHD diagnosis and treatment. The American Medical Association Council on Scientific Affairs concluded that there was little support for the suggestions of over-treatment, 5 and epidemiological data indicate that under-treatment is at least as serious problem as over-treatment. 6 Nevertheless, the results of other studies suggest that stimulant use is quite high in selected school districts or geographic regions. 7 Concerns persist, despite the fact that medications for ADHD have been shown to be quite effective and well-tolerated in a large, long-term randomized multicenter trial. 8 As a result of continuing contro-versy in this area, the Consensus Conference on Diagnosis and Treatment of ADHD 9 was convened in November, 1998. Jensen provides a summary of the conference.
Introduction
A Glimpse Into Key Issues in ADHD Jeffrey H. Newcorn, MD Attention-deficit/hyperactivity disorder (ADHD) is a condition that is characterized by developmentally high levels of inattention, overactivity, and impulsivity, although the extent and distribution of symptoms often varies across individuals. ADHD often begins very early in childhood. Children with this condition are often unable to focus their attention on tasks, are easily distracted, fail to complete assignments, and shift from one play activity to another. They may also be extremely overactive and aggressive. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, groups ADHD symptoms into two domains: inattention and hyperactivity/impulsivity. Some children only manifest symptoms in one of these domains, although the majority have impairments in both. ADHD co-occurs with other psychiatric and cognitive conditions in approximately two thirds of cases. 1 Most common among these are oppositional and conduct problems (up to 50% of some samples), anxiety disorders (often approxiamtely 25% of cases), mood disorders (5% to 15%), and learning disorders (at least 20%). Children with ADHD are at risk for development of conduct and antisocial disorders, substance use disorders, academic underachievement, poor educational and vocational attainment, and secondary mood and anxiety disorders. Moreover, ADHD symptoms frequently persist into adulthood, with the majority of individuals showing some evidence of residual symptomatology or impairment, and a somewhat lower percentage having the full disorder. 2 Although ADHD has long been well known to pediatricians and specialists in child mental health, it was often unfamiliar to other disciplines. However, as information about the range of impairments associated with ADHD and its persistence over the lifespan have become more available, ADHD has attracted considerable interest. Not all of this attention has been positive; there have been concerns regarding the possibility of over-diagnosis and over-treatment, with particular focus on the large increase in stimulant medication use over the past decade. 34 Some have alleged that ADHD is better conceptualized as a problem of temperament, rather than a psychiatric disorder, or a reflection of a mismatch between the developmental needs of children and those of an increasingly achievement oriented society. The public dialogue regarding these issues has led to several comprehensive reviews of ADHD diagnosis and treatment. The American Medical Association Council on Scientific Affairs concluded that there was little support for the suggestions of over-treatment, 5 and epidemiological data indicate that under-treatment is at least as serious problem as over-treatment. 6 Nevertheless, the results of other studies suggest that stimulant use is quite high in selected school districts or geographic regions. 7 Concerns persist, despite the fact that medications for ADHD have been shown to be quite effective and well-tolerated in a large, long-term randomized multicenter trial. 8 As a result of continuing contro-versy in this area, the Consensus Conference on Diagnosis and Treatment of ADHD 9 was convened in November, 1998. Jensen provides a summary of the conference.
Other papers review key areas in the literature and present new data on questions of interest. Schulz et al summarize what is known regarding the neurobiology of ADHD, describing several models that have been presented and examining the degree to which these models are supported by the results of neuropsychological, neurochemical, imaging, and genetic studies. Solanto reviews the empirical basis for the distinction between ADHD combined and primarily inattentive subtypes, raising the question of whether apparently related symptoms of inattention in the two subtypes are driven by different mechanisms. Marks et al present longitudinal data related to the development of aggression in children with ADHD, suggesting that severity of verbal aggression, rather than physical aggression, may be a more potent predictor of the persistence and escalation of aggression over time. Finally, Himmelstein presents pilot data on neuropsychological functioning in adults with ADHD, suggesting that organization of motor output may be more important than inattention over the lifespan.
The goal of this issue of CNS Spectrums is to offer a glimpse into key issues in the field, focusing primarily on neurobiology, developmental psychopathology, and neuropsychology. Despite all that is known about ADHD, there is still much work to be done. Hopefully, the papers in this issue identify fruitful areas for future research. U ! 9
Why expose your patients to the "ups and downs" of traditional carbamazepine therapy?
Switch to Carbatrol®-Second-generation delivery system design that targets the limitations of conventional carbamazepine 1 ' 6
Bioequivalent to immediate-release carbamazepine dosed rigidly Q6h 3
• Peak-to-trough fluctuations are not compromised 3 Absence seizures (petit mal) do not appear to be controlled by carbamazepine. The most frequently reported adverse events (particularly during the initial phases of therapy) are dizziness, drowsiness, unsteadiness, nausea, and vomiting. Adverse events can be minimized by initiating therapy at the lowest possible effective dose. 
Please see brief summary of prescribing information on adjacent pages.
Carbatrol is a registered trademark of Shire Richwood Inc. REPORTED IN ASSOCIATION WITH THE USE OF  CARBAMAZEPINE. DATA FROM A POPULATION-BASED CASE-CONTROL STUDY DEMONSTRATE THAT THE  RISK OF DEVELOPING THESE REACTIONS IS 5-8 TIMES GREATER THAN IN THE GENERAL POPULATION.  HOWEVER, THE OVERALL RISK OF THESE REACTIONS IN THE UNTREATED GENERAL POPULATION IS LOW.  APPROXIMATELY SIX PATIENTS PER ONE MILLION POPULATION PER YEAR FOR AGRANULOCYTOSIS AND  TWO PATIENTS PER ONE MILLION POPULATION PER YEAR FOR APLASTIC ANEMIA.  ALTHOUGH REPORTS OF TRANSIENT OR PERSISTENT DECREASED PLATELET OR WHITE BLOOD CELL  COUNTS ARE NOT UNCOMMON IN ASSOCIATION WITH THE USE OF CARBAMAZEPINE, DATA ARE NOT  AVAILABLE TO ESTIMATE ACCURATELY THEIR INCIDENCE OR OUTCOME. HOWEVER, THE VAST MAJORITY  OF THE CASES OF LEUKOPENIA HAVE NOT PROGRESSED TO THE MORE SERIOUS CONDITIONS OF  APLASTIC ANEMIA OR Baton prescribing Cartotrol, the physician should be thoroughly lamlllar with the details ol ths lull prescribing Information, particularly regarding use with other drugs, especially those which accentuate toxlclty potential.
INDICATIONS AND U8A0E
ol* Is Indicated for use as an antlconvulsant drug. Evidence supporting efficacy of carbamazeplne as an antlconvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types:
1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater Improvements than those with other types. 2. Generalized tonlc-clonlc seizures (grand mal). 3. Mixed seizure patterns which Include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazeplne (see PRECAUTIONS, General).
Trlgsmlml Neuralgia
Carbatrol Is Indicated In the treatment of the pain associated with true trlgemlnal neuralgia. Beneficial results have also been reported In glossopharyngeal neuralgia. This drug Is not a simple analgesic and should not be used for the relief of trivial aches or pains. CONTRAINDICATIONS Carbamazeplne should not be used In patients with a history of previous bone marrow depression, hypersensltlvlty to the drug, or known sensitivity to any of the tricycllc compounds, such as amltrlptyllne, deslpramlne, Imlpramlne, protrlptyllne and nortrlptyllne. Likewise, on theoretical grounds Its use with monoamlne oxldase Inhibitors Is not recommended. Before administration of carbamazeplne, MAO Inhibitors should be discontinued for a minimum of 14 days, or longer If the clinical situation permits.
WARNINGS Uaage In Pregnancy
Carbamazeplne can cause fetal harm when administered to a pregnant woman. Epldemlologlcal data suggest that there may be an association between the use of carbamazeplne during pregnancy and congenital malformations, Including splna blflda. The prescribing physician will wish to weigh the benefits of therapy against the risks In treating or counseling women of chlldbearing potential. If this drug Is used during pregnancy, or If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Retrospective case reviews suggest that, compared with monotherapy, there may be a higher prevalence of teratogenlc effects associated with the use of antlconvulsants In combination therapy. In humans, transplacental passage of carbamazeplne Is rapid (30-60 minutes), and the drug Is accumulated In the fetal tissues, with higher levels found In liver and kidney than In brain and lung. Carbamazeplne has been shown to have adverse effects In reproduction studies In rats when given orally In dosages 10-25 times the maximum human dally dosage (MHDD) of 1200 mg on a mg/kg basis or 1.5-4 times the MHDD on a mg/m 1 basis. In rat teratology studies, 2 of 135 offspring showed kinked ribs at 250 mg/kg and 4 ot 119 offspring at 650 mg/kg showed other anomalies (cleft palate, 1; talipes, 1; anophthalmos, 2). In reproduction studies In rats, nursing offspring demonstrated a lack of weight gain and an unkempt appearance at a maternal dosage level of 200 mg/kg. Antleplleptlc drugs should not be discontinued abruptly In patients In whom the drug Is administered to prevent ma|or seizures because of the strong possibility of precipitating status eplleptlcus with attendant hypoxla and threat to life. In Individual cases where the severity and frequency of the seizure disorder are such that removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although It cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus. Tests to detect defects using current accepted procedures should be considered a part of routine prenatal care In chlldbearing women receiving carbamazeplne. General Patients with a history of adverse hematologlc reaction to any drug may be particularly at risk. Severe dermatologlc reactions, Including toxic epidermal necrolysls (Lyell's syndrome) and Stevens-Johnson syndrome have been reported with carbamazeplne. These reactions have been extremely rare. However, a few fatalities have been reported. Carbamazeplne has shown mild antlchollnerglc activity; therefore, patients with Increased Intraocular pressure should be closely observed during therapy. Because of the relationship of the drug to other tricycllc compounds, the possibility of activation of a latent psychosis and, In elderly patients, of confusion or agitation should be considered.
PRECAUTIONS General
Before Initiating therapy, a detailed history and physical examination should be made. Carbamazeplne should be used with caution In patients with a mixed seizure disorder that Includes atypical absence seizures, since In these patients carbamazeplne has been associated with Increased frequency of generalized convulsions (see INDICATIONS AND USAGE).Therapy should be prescribed only after critical benefitto-risk appraisal In patients with a history of cardiac, hepatic, or renal damage; adverse hematologlc reaction to other drugs; or Interrupted courses of therapy with carbamazeplne.
Information for Pitlents
Patients should be made aware of the early toxic signs and symptoms of a potential hematologlc problem, such as fever, sore throat, rash, ulcers In the mouth, easy bruising, petechlal or purpurlc hemorrhage, and should be advised to report to the physician Immediately If any such signs or symptoms appear. Since dizziness and drowsiness may occur, patients should be cautioned about the hazards of operating machinery or automobiles or engaging In other potentially dangerous tasks. If necessary, the Carbatrol capsules can be opened and the contents sprinkled over food, such as a teaspoon of applesauce or other similar food products. Carbatrol capsules or their contents should not be crushed or chewed.
Laboratory Tests
Complete pretreatment blood counts, Including platelets and possibly retlculocytes and serum Iron, should be obtained as a baseline. If a patient In the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of the drug should be considered If any evidence of significant bone marrow depression develops. Baseline and periodic evaluations of liver function, particularly In patients with a history of liver disease, must be performed during treatment with this drug since liver damage may occur. The drug should be discontinued Immediately In cases of aggravated liver dysfunction or active liver disease. Baseline and periodic eye examinations, Including silt-lamp, funduscopy, and tonometry, are recommended since many phenothlazlnes and related drugs have been shown to cause eye changes. Baseline and periodic complete urlnalysls and BUN determinations are recommended for patients treated with this agent because of observed renal dysfunction. Monitoring of blood levels (see CLINICAL PHARMACOLOGY) has Increased the efficacy and safety of antlconvulsants. This monitoring may be particularly useful In cases of dramatic Increase In seizure frequency and for verification of compliance. In addition, measurement of drug serum levels may aid In determining the cause of toxlclty when more than one medication Is being used. Thyroid function tests have been reported to show decreased values with carbamazeplne administered alone. Hyponatremla has been reported In association with carbamazeplne use, either alone or In combination with other drugs. Interference with some pregnancy tests has been reported.
•Registered trademark of Shire Rtehwood Inc.
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Drug Interactions
Clinically meaningful drug Interactions have occurred with concomitant medications and include, but are not limited to the following: Agents that may effect carbamazeplne platma levels: CYP 3A4 Inhibitors Inhibit carbamazeplne metabolism and can thus Increase plasma carbamazeplne levels. Drugs that have been shown, or would be expected, to Increase plasma carbamazeplne levels Include: cimetidlne, danazol, dlltazem, macrolldes, erythromycln, traleandomycln, darfthromycin, fluoxetlne, loratadine, terfenadlne, Isonlazld, nlaclnamlde, nlcotlnamlde, propoxyphene, ketoconazole, Itraconazole, verapamil, valproate.' CYP 3A4 Inducers can Increase the rate of carbamazeplne metabolism and can thus decrease plasma carbamazeplne levels. Drugs that have been shown, or would be expected, to decrease plasma carbamazeplne levels Include: cisplatln, doxorublcln HCL, felbamate, lifampin*, phenobarbltal, phenytoln, primldone, theophylline. Effect of carbamazeplne on plasma levels ol concomitant agent*: Carbatrol Increases levels of clomlpramlne HCL, phenytoln and primldone. Carbatrol Induces hepatic CYP activity. Carbatrol causes, or would be expected to cause decreased levels of the following: acetaminophen, alprazolam, clonazepam, clozaplne, dlcumarol, doxycycline, athosuximlde, haloperldol, methsuxlmlde, oral contraceptives, phensuxlmlde, phenytoln, theophylline, valproate, warfarin. The doses of these drugs may therefore have to be increased when carbamazeplne la added to the therapeutic regimen. Concomitant administration of carbamazeplne and lithium may Increase the risk of neurotoxlc side effects. Alterations of thyroid function have been repotted In combination therapy with other antlconvulsant medications. Breakthrough bleeding has been reported among patients receiving concomitant oral contraceptives and their reliability may be adversely affected. Carclnoganesls, Mutagenasls, Impairment ol Fertility Administration of carbamazeplne to Sprague-Dawley rats for two years In the diet at doses of 25,75, and 250 mgAg/day (low dose approximately 0.2 times the maximum human dally dose of 1200 mg on a mg/m 1 basis), resulted In a dose-related Increase In the Incidence of hepatocellular tumors In females and of benign Interstitial cell adenomas In the testes of males. Carbamazeplne must, therefore, be considered to be carcinogenic In Sprague-Dawley rats. Bacterial and mammalian mutagenlclty studies using carbamazeplne produced negative results. The significance of these findings relative to the use of carbamazeplne In humans Is, at present, unknown. Uaage In Pregnancy Pregnancy Category D (See WARNINGS)
